I believe the future of Intellect is already written!
I have selected the phrases of Dr. Chain in a letter to shareholders:
March 29, 2013
... trip to Europe, which included 27 meetings in 10 days!
1) ... The vast majority of these meetings had to do with the strategic plan I outlined in my letter to you of February 13, 2013: namely, to move forward aggressively with our CONJUMAB-A and tau immunotherapy programs, which have attracted interest from the pharmaceutical industry and institutional investors, especially in Europe. ...
2) ... I was encouraged by several examples of assays being developed to evaluate drug compounds targeting tau that could be helpful to Intellect. ( CHF 5074 ? ) ...
3) ... Some of these meetings were with large pharmaceutical companies to discuss potential partnering relationships. ...
4) ... Other pre-arranged meetings were with specialist contract research organizations and regulatory specialists that can help enormously with creating a high-value drug compound dossier to facilitate partnering activities in the future. ( Evli ? ) ...
5) ... I was pleased to discover a number of newly developed sophisticated tools that could be applied to test and optimize Intellect's drug candidates. ...
6) ... Back in New York, we have been exceedingly busy following up on ongoing licensing conversations and adding further detail to the development programs so that we are in position to proceed aggressively pending securing adequate financial resources. ...
-------------------------------------------------------------------------
Note:
Intellect has been mentioned twice in steps 2 and 4.
He seems genuinely interested in the future of the intellect and not interested in his personal gain.
-
